
FDA Grants Fast Track Designation to BI-1808 in Select Cutaneous T-Cell Lymphoma
The FDA has granted breakthrough therapy designation to the first-in-class anti–tumor necrosis factor receptor 2 (TNFR2) antibody, BI-1808 for the treatment of adults with 2 cutaneous T-cell lymphoma (CTCL) subtypes: relapsed or refractory mycosis …